CN112763636B - Peptide map analysis method - Google Patents
Peptide map analysis method Download PDFInfo
- Publication number
- CN112763636B CN112763636B CN202011419204.0A CN202011419204A CN112763636B CN 112763636 B CN112763636 B CN 112763636B CN 202011419204 A CN202011419204 A CN 202011419204A CN 112763636 B CN112763636 B CN 112763636B
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- uplc
- volume fraction
- peptide
- analysis method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 48
- 238000004458 analytical method Methods 0.000 title claims abstract description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 claims abstract description 33
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019253 formic acid Nutrition 0.000 claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 12
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims abstract description 12
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical group CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 238000004925 denaturation Methods 0.000 claims abstract description 5
- 230000036425 denaturation Effects 0.000 claims abstract description 5
- 238000001514 detection method Methods 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 102000007079 Peptide Fragments Human genes 0.000 claims description 10
- 108010033276 Peptide Fragments Proteins 0.000 claims description 10
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- 238000012510 peptide mapping method Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 108010059378 Endopeptidases Proteins 0.000 claims description 5
- 102000005593 Endopeptidases Human genes 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000004807 desolvation Methods 0.000 claims description 3
- 239000012071 phase Substances 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229960000789 guanidine hydrochloride Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Name of instrument | Instrument type |
UPLC | Waters-H-class plus |
Constant temperature metal bath | DTK200-4 of Hangzhou Mi Europe Instrument Co., Ltd |
Vortex oscillator | Hangzhou Miou Instrument Co Ltd MIX-25P |
High-speed refrigerated centrifuge | Thermo-LEGEND MICRO 21R |
Centrifugal machine | Thermo-ST16R |
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011419204.0A CN112763636B (en) | 2020-12-07 | 2020-12-07 | Peptide map analysis method |
PCT/CN2020/141486 WO2022121040A1 (en) | 2020-12-07 | 2020-12-30 | Peptide mapping method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011419204.0A CN112763636B (en) | 2020-12-07 | 2020-12-07 | Peptide map analysis method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112763636A CN112763636A (en) | 2021-05-07 |
CN112763636B true CN112763636B (en) | 2022-04-19 |
Family
ID=75693468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011419204.0A Active CN112763636B (en) | 2020-12-07 | 2020-12-07 | Peptide map analysis method |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112763636B (en) |
WO (1) | WO2022121040A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115097041B (en) * | 2022-06-28 | 2023-12-15 | 中国农业科学院北京畜牧兽医研究所 | Kit for detecting luteinizing hormone by PRM (PRM), detection method and application |
CN116908321B (en) * | 2023-06-21 | 2024-05-31 | 南京汉欣医药科技有限公司 | Protamine sulfate peptide map detection method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102495169A (en) * | 2011-11-16 | 2012-06-13 | 江南大学 | Purifying and analyzing identification method for anti-oxidative peptide after controlled-enzymatic hydrolysis of laver |
CN108267534A (en) * | 2016-12-31 | 2018-07-10 | 江苏众红生物工程创药研究院有限公司 | The Peptides figure analysis method of polyethylene glycol modified protein drug |
CN110297050A (en) * | 2019-07-23 | 2019-10-01 | 天津市药品检验研究院 | A kind of discrimination method of insulin mass spectrum peptide figure and application |
CN110988244A (en) * | 2019-12-23 | 2020-04-10 | 上海景峰制药有限公司 | Nexiridin peptide map analysis method and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601542B2 (en) * | 2006-02-08 | 2009-10-13 | Florida State University Research Foundation | Analytical method for protein mapping using hydrogen/deuterium exchange |
JP5977733B2 (en) * | 2011-03-08 | 2016-08-24 | 株式会社三和化学研究所 | Analysis method |
CN107827960B (en) * | 2017-10-26 | 2021-06-15 | 中国食品药品检定研究院 | Method for quantitatively detecting L1 protein of HPV |
MX2020011458A (en) * | 2018-05-03 | 2020-12-07 | Washington University St Louis | Methods of diagnosing and treating based on site-specific tau phosphorylation. |
CN110734485A (en) * | 2019-09-26 | 2020-01-31 | 浙江海洋大学 | protein biomarkers in the aging process of Sepiella maindroni |
CN111239273A (en) * | 2020-01-22 | 2020-06-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | Mass spectrum analysis method for rituximab pharmacokinetic study |
-
2020
- 2020-12-07 CN CN202011419204.0A patent/CN112763636B/en active Active
- 2020-12-30 WO PCT/CN2020/141486 patent/WO2022121040A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102495169A (en) * | 2011-11-16 | 2012-06-13 | 江南大学 | Purifying and analyzing identification method for anti-oxidative peptide after controlled-enzymatic hydrolysis of laver |
CN108267534A (en) * | 2016-12-31 | 2018-07-10 | 江苏众红生物工程创药研究院有限公司 | The Peptides figure analysis method of polyethylene glycol modified protein drug |
CN110297050A (en) * | 2019-07-23 | 2019-10-01 | 天津市药品检验研究院 | A kind of discrimination method of insulin mass spectrum peptide figure and application |
CN110988244A (en) * | 2019-12-23 | 2020-04-10 | 上海景峰制药有限公司 | Nexiridin peptide map analysis method and application thereof |
Non-Patent Citations (5)
Title |
---|
A modified peptide mapping strategy for quantifying site-specific deamidation by electrospray time-of-flight mass spectrometry;Steven D. Stroop;《RAPID COMMUNICATIONS IN MASS SPECTROMETRY》;20071231;第21卷;第830-836页 * |
EVALUATION OF A CANDIDATE NATIONAL STANDARD FOR RECOMBINANT HUMAN ERYTHROPOIETIN BY UPLC/HDMS;Anna Carolina Machado Marinho 等;《Sobre o Repositório Arca》;20131231;第79-80页 * |
Glycosylation Profiling of α/β T Cell Receptor Constant Domains Expressed in Mammalian Cells;Kai Zhang 等;《Synthetic Antibodies: Methods and Protocols, Methods in Molecular Biology》;20171231;第1575卷;第197-213页 * |
Kai Zhang 等.Glycosylation Profiling of α/β T Cell Receptor Constant Domains Expressed in Mammalian Cells.《Synthetic Antibodies: Methods and Protocols, Methods in Molecular Biology》.2017,第1575卷第197-213页. * |
同位素稀释质谱法测定乳及含乳饮料中的酪蛋白含量;孙姗姗 等;《食品安全质量检测学报》;20180630;第9卷(第12期);第3147-3157页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112763636A (en) | 2021-05-07 |
WO2022121040A1 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kaiser et al. | Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use | |
CN112763636B (en) | Peptide map analysis method | |
Zhou et al. | An investigation into the human serum “interactome” | |
González-Buitrago et al. | Urinary proteomics | |
Henningsen et al. | Application of zwitterionic detergents to the solubilization of integral membrane proteins for two‐dimensional gel electrophoresis and mass spectrometry | |
US20070202539A1 (en) | Methods for quantitative proteome analysis of glycoproteins | |
US20160266141A1 (en) | Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic | |
CN111381043B (en) | Sample pretreatment composition suitable for mass spectrometry detection, sample pretreatment method and application | |
JP2024050535A (en) | Detection of amyloid beta by mass spectrometry | |
US11619635B2 (en) | Process for ultra-sensitive quantification of target analytes in complex biological systems | |
CN111381044B (en) | Pretreatment composition, pretreatment method and application of sugar chain structure abnormal protein suitable for mass spectrometry detection | |
CN114705849A (en) | Mass spectrum method for absolute quantification of cystatin C in serum based on SILAC | |
US20050196789A1 (en) | Preparation of biologically derived fluids for biomarker determination by mass spectrometry | |
CN107102152B (en) | The protein marker of urine myocardial infarction and its purposes in diagnosis and prognosis | |
Shively et al. | Highlights of protein structural analysis | |
Sakaguchi et al. | Quantification of peptides using N‐terminal isotope coding and C‐terminal derivatization for sensitive analysis by micro liquid chromatography‐tandem mass spectrometry | |
CN107014935B (en) | A kind of IgG sugar-type detection batch pre-treating method of blood plasma or serum | |
WO2012097276A2 (en) | Bcl-2-like protein 11 srm/mrm assay | |
CN110045053A (en) | A kind of QuEChERS pre-treating method of the analysis of the amphetamines suitable for blood | |
TW201940883A (en) | A dual-column LC-MS system and methods of use thereof | |
CN108956791B (en) | Method for screening protein biomarkers in large scale | |
EP3529617B1 (en) | Immobilized analytes | |
Schiffer et al. | Exploring the uremic toxins using proteomic technologies | |
CN111518868A (en) | Application of PGAM5 as diagnosis marker and treatment target of oligoasthenospermia | |
Lee et al. | Development of a parallel microbore hollow fiber enzyme reactor platform for online 18O-labeling: Application to lectin-specific lung cancer N-glycoproteome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220518 Address after: 518107 floor 1, building 6, Weiguang Life Science Park (phase I), west of Luozi Road, Zhenmei community, Xinhu street, Guangming District, Shenzhen, Guangdong Patentee after: Shenzhen hanteng Biotechnology Co.,Ltd. Patentee after: Foshan hanteng Biotechnology Co.,Ltd. Patentee after: CANTONBIO Co.,Ltd. Patentee after: Foshan Pu Jin Bioisystech Co.,Ltd. Address before: 528000 room 511, 5 / F, building a, Central Europe center, 2 Lingnan Avenue South, Lecong Town, Shunde District, Foshan City, Guangdong Province Patentee before: Foshan hanteng Biotechnology Co.,Ltd. Patentee before: CANTONBIO Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240204 Address after: Room 301, Building B, No. 19 Nanxiang Third Road, Huangpu District, Guangzhou City, Guangdong Province, 510320 Patentee after: CANTONBIO Co.,Ltd. Country or region after: China Patentee after: Foshan hanteng Biotechnology Co.,Ltd. Address before: 518107 floor 1, building 6, Weiguang Life Science Park (phase I), west of Luozi Road, Zhenmei community, Xinhu street, Guangming District, Shenzhen, Guangdong Patentee before: Shenzhen hanteng Biotechnology Co.,Ltd. Country or region before: China Patentee before: Foshan hanteng Biotechnology Co.,Ltd. Patentee before: CANTONBIO Co.,Ltd. Patentee before: Foshan Pu Jin Bioisystech Co.,Ltd. |
|
TR01 | Transfer of patent right |